We have systematically investigated the therapeutic potential of cationic
liposome-mediated neurotrophic gene transfer for treatment of CNS injury. Following determination of optimal transfection conditions, we examined the effects of dimethylaminoethane-carbamoyl-
cholesterol (
DC-Chol)
liposome-mediated
NGF cDNA transfection in injured and uninjured primary septo-hippocampal cell cultures and rat brains. In in vitro studies, we detected an increase of
NGF mRNA in cultures 1 day after transfection. Subsequent ELISA and PC12 cell
biological assays confirmed that cultured cells secreted soluble active
NGF into the media from day 2 after gene transfection. Further experiments showed that such
NGF gene transfection reduced the loss of chol- ine
acetyltransferase (ChAT) activity in cultures following
calcium-dependent depolarization injury. In in vivo studies, following
intraventricular injections of
NGF cDNA complexed with
DC-Chol liposomes, ELISA detected nine- to 12-fold increases of
NGF in rat CSF. Further studies showed that
liposome/
NGF cDNA complexes could attenuate the loss of
cholinergic neuronal immunostaining in the rat septum after
traumatic brain injury (TBI). Since deficits in
cholinergic neurotransmission are a major consequence of TBI, our studies demonstrate for the first time that
DC-Chol liposome-mediated
NGF gene transfection may have therapeutic potential for treatment of
brain injury.